Elicio Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Elicio Therapeutics, Inc. (ELTX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $490.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $247.00K, a 8.33% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $243.00K, a 8.00% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $237.00K, a 7.73% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $234.00K, a 8.33% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $924.00K, a 7.82% increase from fiscal 2024.
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $857.00K, a 8.76% increase from fiscal 2023.
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $788.00K, a 18.14% increase from fiscal 2022.
- Elicio Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $667.00K, a 6.06% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $490.00K 10-Q · filed 2026-08-13 | $727.00K derived: sum of 3 quarters · filed 2026-08-13 | $961.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $243.00K 10-Q · filed 2026-05-11 | $480.00K derived: sum of 2 quarters · filed 2026-05-11 | $714.00K derived: sum of 3 quarters · filed 2026-05-11 | $942.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $471.00K derived: sum of 2 quarters · filed 2026-03-12 | $699.00K derived: sum of 3 quarters · filed 2026-08-13 | $924.00K 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $234.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $462.00K derived: sum of 2 quarters · filed 2026-08-13 | $687.00K 10-Q · filed 2025-11-13 | $907.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $228.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $453.00K 10-Q · filed 2026-08-13 | $673.00K derived: sum of 3 quarters · filed 2026-08-13 | $889.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $225.00K 10-Q · filed 2026-05-11 | $445.00K derived: sum of 2 quarters · filed 2026-05-11 | $661.00K derived: sum of 3 quarters · filed 2026-05-11 | $874.00K derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $436.00K derived: sum of 2 quarters · filed 2026-03-12 | $649.00K derived: sum of 3 quarters · filed 2026-03-12 | $857.00K 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $216.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $429.00K derived: sum of 2 quarters · filed 2025-11-13 | $637.00K 10-Q · filed 2025-11-13 | $843.00K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $421.00K 10-Q · filed 2025-08-07 | $627.00K derived: sum of 3 quarters · filed 2025-08-07 | $812.00K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $208.00K 10-Q · filed 2025-05-13 | $414.00K derived: sum of 2 quarters · filed 2025-05-13 | $599.00K derived: sum of 3 quarters · filed 2025-05-13 | $996.00K derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $391.00K derived: sum of 2 quarters · filed 2025-03-31 | $788.00K derived: sum of 3 quarters · filed 2025-03-31 | $788.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $582.00K derived: sum of 2 quarters · filed 2024-11-13 | $582.00K 10-Q · filed 2024-11-13 | $776.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $397.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $397.00K 10-Q · filed 2024-08-13 | $591.00K derived: sum of 3 quarters · filed 2024-08-13 | $781.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | $26.00K 10-Q · filed 2023-05-10 | $194.00K derived: sum of 2 quarters · filed 2024-05-15 | $384.00K derived: sum of 3 quarters · filed 2024-05-15 | $471.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $384.00K derived: sum of 2 quarters · filed 2024-03-29 | $471.00K derived: sum of 3 quarters · filed 2024-03-29 | $667.00K 10-K · filed 2024-03-29 | $813.00K 10-K · filed 2023-03-17 | |||
| 2022-09-30 | $190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $277.00K derived: sum of 2 quarters · filed 2023-11-13 | $473.00K 10-Q · filed 2023-11-13 | $603.00K 10-Q · filed 2022-11-14 | $664.00K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $283.00K 10-Q · filed 2023-08-14 | $397.00K 10-Q · filed 2022-08-15 | $474.00K derived: sum of 3 quarters · filed 2023-08-14 | $661.00K derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $196.00K 10-Q · filed 2023-05-10 | $387.00K derived: sum of 2 quarters · filed 2023-05-10 | $574.00K derived: sum of 3 quarters · filed 2023-05-10 | $757.00K derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $378.00K derived: sum of 2 quarters · filed 2023-03-17 | $561.00K derived: sum of 3 quarters · filed 2023-03-17 | $710.00K 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | $187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $370.00K derived: sum of 2 quarters · filed 2022-11-14 | $519.00K 10-Q · filed 2022-11-14 | $653.00K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $332.00K 10-Q · filed 2022-08-15 | $466.00K derived: sum of 3 quarters · filed 2022-08-15 | $595.00K derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $149.00K 10-Q · filed 2022-05-16 | $283.00K derived: sum of 2 quarters · filed 2022-05-16 | $412.00K derived: sum of 3 quarters · filed 2022-05-16 | $535.00K derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $263.00K derived: sum of 2 quarters · filed 2022-03-30 | $386.00K derived: sum of 3 quarters · filed 2022-03-30 | $530.00K 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $252.00K derived: sum of 2 quarters · filed 2021-11-12 | $396.00K 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $267.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $144.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |